Cytokinetics IncCYTK
ASignal's systematic analysis rates CYTK as Bearish.
Reflects the latest available analysis · analyzed Aug 24, 2026
The case on CYTK
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Current price near Bollinger Lower Band suggesting potential reversal
- Positive MACD histogram expansion indicating short-term momentum stabilization
- High cash position with $1.17B total cash and strong liquidity ratios (current ratio 6.66x)
- Low beta (0.38x) indicating lower volatility relative to market
- Negative price momentum and trading below both SMA20 and SMA50
- MACD below signal line despite histogram improvement
- Severe negative operating margin (-625.95%)
- Negative revenue growth (YoY: -57.10%)
- Negative free cash flow ($-397.41M) and operating cash flow ($-555.45M)
- High valuation multiples: EV/Revenue 161.69x, PS 158.38x despite negative earnings
See the full verdict on CYTK
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CYTK
Most investors never get a second opinion, let alone several. ASignal runs CYTK past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.